Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | NAMPT | P43490 | 2/20 | 0.39 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.37 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.37 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.37 |
| ▸ | GPR183 | P32249 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.35 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.35 |
| ▸ | TPSD1 | Q9BZJ3 | 1/20 | 0.35 |
| ▸ | TPSG1 | Q9NRR2 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20328001 | 0.90 | KDM4E (0.50) | KDM4ENAMPTGPR183HSD17B10TPSAB1 | |
| SCHEMBL18704939 | 0.87 | HRH3 (0.47) | NAMPTTLR9TLR8TLR7HRH3 | |
| SCHEMBL17540513 | 0.81 | NAMPT (0.42) | NAMPTTLR9TLR8TLR7ALOX15 | |
| SCHEMBL13779970 | 0.79 | NAMPT (0.45) | NAMPTHRH3ALOX15TSHRHSD17B10 | |
| SCHEMBL18704942 | 0.78 | HRH3 (0.42) | NAMPTHRH3 | |
| SCHEMBL22030592 | 0.78 | RET (0.35) | — | |
| SCHEMBL18713080 | 0.78 | NAMPT (0.45) | KDM4ENAMPTHRH3HSD17B10TPSAB1 | |
| SCHEMBL13469911 | 0.77 | NAMPT (0.44) | NAMPTTLR9TLR8TLR7ALOX15 | |
| SCHEMBL12522667 | 0.76 | NAMPT (0.45) | KDM4ENAMPTALOX15TSHRHSD17B10 | |
| SCHEMBL20328051 | 0.76 | NAMPT (0.39) | NAMPTTLR9TLR8TLR7HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190127375-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2019-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190127375-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, ROR1, BRAF | KDM4E 695/4885NAMPT 3149/4885TLR9 3792/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.